Table 3.
Omalizumab Effectiveness at T4–6 and T12 in Patients without or with AD
| Minors | Adults | Total (Minors and Adults) | ||||
|---|---|---|---|---|---|---|
| AD: No | AD: Yes | AD: No | AD: Yes | AD: No | AD: Yes | |
| T4–6, N | 99 | 50 | 683 | 40 | 782 | 90 |
| GETE score | ||||||
| Responders, n (%) [95% CI] |
73 (73.7) [65.07; 82.41] |
42 (84.0) [73.84; 94.16] |
457 (66.9) [63.38; 70.44] |
29 (72.5) [58.66; 86.34] |
530 (67.8) [64.50; 71.05] |
71 (78.9) [70.46; 87.32] |
| Change in yearly asthma exacerbation rate | ||||||
| Responders, n (%) [95% CI] |
73 (73.7) [65.07; 82.41] |
44 (88.0) [78.99; 97.01] |
486 (71.2) [67.76; 74.55] |
28 (70.0) [55.80; 84.20] |
559 (71.5) [68.32; 74.65] |
72 (80.0) [71.74; 88.26] |
| T12, N | 88 | 41 | 546 | 31 | 634 | 72 |
| Yearly rate of asthma exacerbation | ||||||
| n | 59 | 33 | 274 | 15 | 333 | 48 |
| Mean±SD | 1.2±1.60 | 1.0±1.66 | 1.4±2.02 | 1.1±1.61 | 1.4±1.95 | 1.0±1.63 |
| Change in yearly asthma exacerbation rate | ||||||
| n | 59 | 33 | 274 | 15 | 333 | 48 |
| Responders, n (%) | 47 (79.7) | 30 (90.9) | 210 (76.6) | 12 (80.0) | 257 (77.2) | 42 (87.5) |
| Yearly rate of hospitalisation | ||||||
| n | 87 | 40 | 537 | 31 | 624 | 71 |
| Mean±SD | 0.2±0.60 | 0.2±0.73 | 0.2±0.58 | 0.3±0.85 | 0.2±0.59 | 0.3±0.79 |
| Change in yearly hospitalisation rate | ||||||
| n | 50 | 20 | 218 | 16 | 268 | 36 |
| Mean±SD | −67.3%±60.85 | −87.8%±28.73 | −74.3%±52.10 | −49.2%±80.77 | −73.0%±53.79 | −70.7%±60.20 |
| Improvement in AC after omalizumab initiation† | ||||||
| n | 74 | 41 | 290 | 29 | 364 | 70 |
| Yes, n (%) | 58 (78.4) | 36 (87.8) | 142 (49.0) | 12 (41.4) | 200 (54.9) | 48 (68.6) |
Note: †Only patients with AC at omalizumab initiation are included in the analysis.
Abbreviations: AC, allergic comorbidities; AD, atopic dermatitis; CI, confidence interval; GETE, Global Evaluation of Treatment Effectiveness; SD, standard deviation; n, patients with available data.